UK biotech Bicycle Therapeutics has raised £40 million ($52m) in a new funding round to help it progress its pipeline, including its lead compound, a first-in-class cancer treatment. The company ...

Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 3,940,000 ...

Cancer Research UK and its commercialisation arm are to work with UK biotech firm Bicycle Therapeutics on a novel approach to targeting cancer. Bicycle Therapeutics has developed a new class of ...

JPMorgan Chase & Co. raised its holdings in shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) by 26.8% during the 3rd quarter, according to the company in its most recent 13F filing with ...

Bicycle Therapeutics' BT8009 offers strong safety and efficacy. Find out why BCYC stock could be a buy, despite recent volatility and awaiting mid-2025 data.

As an investor, mistakes are inevitable. But you have a problem if you face massive losses more than once in a ...

Bicycle Therapeutics plc (NASDAQ:BCYC) reported Q2 EPS of ($0.90), $0.06 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.38 million versus the ...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...

Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company currently valued at $1.05 billion, is garnering attention from analysts for its innovative Bicycle platform technology ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology ...